Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financi...( CAMBRIDGE Mass. Oct. 30 /- Idenix...)

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008. At September 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $60.1 million.

2008 Year-to-Date Business Highlights

-- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log10 after seven days of treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing cohorts (n=8 per treatment group). Patients receiving placebo (n=8) had a mean viral load increase of 0.10 log10 over the same treatment period. The safety profile of IDX899 observed during this study was comparable to placebo, with no serious adverse events reported and no pattern of adverse events or laboratory abnormalities observed on treatment. Additionally, no patients who received treatment discontinued the study.

-- Idenix also continued to advance its HCV discovery and development programs, successfully completing a first-in-man phase I study of IDX184, a nucleotide prodrug candidate, and initiating the IND-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.

"As we advance our HCV and HIV discovery and devel
'/>"/>